JEWELFISH

E561098

JEWELFISH is a clinical trial study evaluating the safety and efficacy of risdiplam in individuals with spinal muscular atrophy who were previously treated with other SMA therapies.

Jump to: Statements Referenced by

Statements (46)

Predicate Object
instanceOf clinical trial
interventional study
pharmacological trial
abbreviation NCT03032172
ageGroup adolescents
adults
children
aimsTo assess safety of switching to or adding risdiplam after prior SMA therapies
collaborator PTC Therapeutics NERFINISHED
SMA Foundation NERFINISHED
conditionSubtype 5q-associated spinal muscular atrophy
dataTypeCollected efficacy data
pharmacodynamic data
pharmacokinetic data
safety data
design multicenter
open-label
single-arm
drugClass SMN2 splicing modifier
drugTarget SMN2 pre-mRNA splicing
endpoint incidence of adverse events
laboratory abnormalities
motor function measures
pharmacokinetic parameters of risdiplam
serious adverse events
evaluates risdiplam NERFINISHED
focusesOn previously treated SMA population
geographicScope international
hasOralFormulation risdiplam NERFINISHED
includesPriorTherapy nusinersen NERFINISHED
onasemnogene abeparvovec
other investigational SMA treatments
intervention risdiplam
phase Phase 2
population individuals with spinal muscular atrophy previously treated with other SMA therapies
primaryObjective to evaluate the safety of risdiplam in previously treated SMA patients
registrationAuthority ClinicalTrials.gov NERFINISHED
routeOfAdministration oral
secondaryObjective to evaluate the pharmacokinetics of risdiplam
to explore efficacy of risdiplam
sponsor F. Hoffmann-La Roche Ltd NERFINISHED
Roche NERFINISHED
sponsorCountry Switzerland NERFINISHED
studiesCondition spinal muscular atrophy
therapeuticArea neuromuscular disease
rare disease

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

risdiplam clinicalTrialProgram JEWELFISH